When Should a Biotech Startup Raise Venture Capital?

Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

Equity financing can be the right choice when the company has a credible product path, the next milestones require substantial capital, and reaching them quickly has meaningful competitive or strategic value.

• The product concept and initial indication are defined.
• Core technical feasibility has been demonstrated.
• The IP position is understood well enough for diligence.
• The regulatory pathway is reasonably mapped.
• The company can explain the market, customer, and value proposition.
• There is a milestone-based use of proceeds tied to value creation.
• The team can credibly execute the funded plan.
  

An investor meeting should not be the first time a founder is forced to define the product, target customer, regulatory path, or capital required to reach a meaningful inflection point.

• The pitch is primarily about the platform rather than the first product.
• The financing ask is based on runway instead of milestones.
• Customer discovery has not been performed.
• Key license or IP terms are unresolved.
• The regulatory route could materially change the development budget.
• The company cannot explain what the next round would finance.
  

Ask: If we raised equity today, would that capital accelerate a path we understand—or would it primarily pay us to discover what the path is? The first situation can justify institutional capital. The second often suggests more de-risking is needed.

BYB Takeaway

Raise venture capital when it can accelerate a defined, valuable development path—not simply because venture capital is available.

Use non-dilutive and milestone-driven resources to improve the terms of the equity you eventually raise.